Table 1.
Cohort details.
| Case # (male ♂/female♀) | MGMT promoter methylation status; M: >13%, U: <13% | Treatment received between specimens | Age at diagnosis (years) | Time to recurrence (diagnosis to 2nd surgery, months) | Overall survival since glioblastoma diagnosis (months) | |
|---|---|---|---|---|---|---|
| Pre-treatment specimen (a) | Post-treatment specimen (b) | |||||
| 4♂ | U | U | Stupp | 53 | 6 | 18 |
| 5♂ | U | U | Stupp | 63 | 35 | 50 |
| 10♂ | U | U | Stupp | 81 | 7 | 13 |
| 19♀ | U | U | Stupp | 57 | 14 | 15 |
| 20♂ | U | U | Stupp | 60 | 7 | 17 |
| 25♂ | M | M | Stupp | 60 | 7 | 9 |
| 29♂ | U | U | Stupp | 40 | 29 | 47 |
| 33♀ | U | U | Stupp | 64 | 11 | 18 |
| 38♂ | U | U | Stupp | 54 | 3 | 15 |
| 40♀ | U | U | Stupp | 48 | 3 | 10 |
| 42♀ | U | U | Stupp | 64 | 7 | 19 |
| 23♀ | U | U | RT-adjuvant TMZ | 76 | 4 | 10 |
| 30♂ | M | M | RT-adjuvant TMZ | 64 | 3 | 3 |
| 35♂ | U | U | RT-adjuvant TMZ | 78 | 10 | 12 |
| 26♂ | M (13.75) | U (2.0) | RT-TMZ Procarb | 35 | 31 | 40 |
| 7♂ | M (15.75) | U (2.0) | RT-Procarb TMZ Cilengtide | 44 | 13 | 22 |
| 13♀ | U | U | RT-Procarb TMZ Cilengtide | 58 | 3 | 12 |
| 16♂ | U | U | RT-Procarb TMZ Cilengtide | 69 | 4 | 15 |
| 32♀ | U | U | RT-Procarb TMZ Cilengtide | 41 | 13 | 33 |
| Mean | 58.4 | 11.1 | 19.9 | |||
| Median | 60 | 7 | 15 | |||
M, Methylated promoter; U, Unmethylated promoter; RT, radiotherapy; TMZ, temozolomide chemotherapy; Stupp, concurrent RT+TMZ followed by adjuvant TMZ. For cases where variability between specimens was detected; the percentage methylation is shown in brackets.